Esperion Therapeutics to Present at Jefferies 2014 Global Healthcare Conference

Presentation and Webcast on Thursday, June 5 at 2:30 p.m. Eastern Time

Business Wire

ANN ARBOR, Mich.--(BUSINESS WIRE)--

Esperion Therapeutics Inc. (ESPR), a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers, today announced the Company will present at the Jefferies 2014 Global Healthcare Conference in New York City, N.Y. Tim M. Mayleben, president and chief executive officer, will provide an update on the company on Thursday, June 5 at 2:30 p.m. Eastern Time.

A live, listen-only webcast of the presentation can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the call will be available approximately one hour after completion of the call and will be archived on the Company's website for 90 days following the event.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with the currently available LDL-cholesterol lowering therapies. ETC-1002 is being developed primarily for patients intolerant of statins with elevated levels of LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently underway and build upon a successful and comprehensive Phase 1 and Phase 2 program. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.

Contact:
Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com
or
Investor Contact:
Westwicke Partners
Jordan Kohnstam, 443.450.4189
jordan.kohnstam@westwicke.com

Rates

View Comments (0)